- Home
- ONCY vs NSPR Comparison
ONCY vs NSPR Comparison
Compare ONCY & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONCY
- NSPR
- Stock Information
- Founded
- ONCY 1998
- NSPR 2005
- Country
- ONCY Canada
- NSPR United States
- Employees
- ONCY N/A
- NSPR N/A
- Industry
- ONCY Pharmaceuticals and Biotechnology
- NSPR Medical/Dental Instruments
- Sector
- ONCY Health Care
- NSPR Health Care
- Exchange
- ONCY Nasdaq
- NSPR Nasdaq
- Market Cap
- ONCY 89.7M
- NSPR 99.7M
- IPO Year
- ONCY 1999
- NSPR N/A
- Fundamental
- Price
- ONCY $1.02
- NSPR $1.95
- Analyst Decision
- ONCY Strong Buy
- NSPR Strong Buy
- Analyst Count
- ONCY 5
- NSPR 2
- Target Price
- ONCY $5.00
- NSPR $4.50
- AVG Volume (30 Days)
- ONCY 948.7K
- NSPR 118.1K
- Earning Date
- ONCY 11-07-2025
- NSPR 11-04-2025
- Dividend Yield
- ONCY N/A
- NSPR N/A
- EPS Growth
- ONCY N/A
- NSPR N/A
- EPS
- ONCY N/A
- NSPR N/A
- Revenue
- ONCY N/A
- NSPR $7,779,000.00
- Revenue This Year
- ONCY N/A
- NSPR $7.48
- Revenue Next Year
- ONCY N/A
- NSPR $104.39
- P/E Ratio
- ONCY N/A
- NSPR N/A
- Revenue Growth
- ONCY N/A
- NSPR 14.04
- 52 Week Low
- ONCY $0.33
- NSPR $1.77
- 52 Week High
- ONCY $1.51
- NSPR $3.80
- Technical
- Relative Strength Index (RSI)
- ONCY 37.21
- NSPR 22.72
- Support Level
- ONCY $0.92
- NSPR $2.05
- Resistance Level
- ONCY $1.05
- NSPR $2.40
- Average True Range (ATR)
- ONCY 0.08
- NSPR 0.15
- MACD
- ONCY -0.02
- NSPR -0.03
- Stochastic Oscillator
- ONCY 25.00
- NSPR 29.05
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.
About NSPR InspireMD Inc.
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.